BioNTech Ownership

22UA Stock  EUR 103.00  4.40  4.46%   
BioNTech holds a total of 242.68 Million outstanding shares. BioNTech SE shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.0 percent of BioNTech SE outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as BioNTech in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioNTech, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

BioNTech Stock Ownership Analysis

About 64.0% of the company shares are owned by insiders or employees . The book value of BioNTech was presently reported as 76.45. The company has Price/Earnings To Growth (PEG) ratio of 0.04. BioNTech SE recorded earning per share (EPS) of 38.32. The entity last dividend was issued on the 2nd of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people. For more info on BioNTech SE please contact the company at 49 6131 9084 0 or go to https://www.biontech.de.

BioNTech Outstanding Bonds

BioNTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioNTech SE uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioNTech bonds can be classified according to their maturity, which is the date when BioNTech SE has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in BioNTech Stock

When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.